Cytosorbents Statistics
Total Valuation
Cytosorbents has a market cap or net worth of $50.03 million. The enterprise value is $71.15 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytosorbents has 54.68 million shares outstanding. The number of shares has increased by 19.27% in one year.
| Current Share Class | 54.68M |
| Shares Outstanding | 54.68M |
| Shares Change (YoY) | +19.27% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 10.87% |
| Owned by Institutions (%) | 27.78% |
| Float | 45.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.27 |
| Forward PS | 1.17 |
| PB Ratio | 3.84 |
| P/TBV Ratio | 3.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.97, with a Debt / Equity ratio of 2.06.
| Current Ratio | 1.97 |
| Quick Ratio | 1.46 |
| Debt / Equity | 2.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -25.76 |
Financial Efficiency
Return on equity (ROE) is -118.50% and return on invested capital (ROIC) is -34.88%.
| Return on Equity (ROE) | -118.50% |
| Return on Assets (ROA) | -27.93% |
| Return on Capital (ROIC) | -34.88% |
| Revenue Per Employee | $202,901 |
| Profits Per Employee | -$100,376 |
| Employee Count | 186 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 4.52 |
Taxes
| Income Tax | -813,739 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.31% in the last 52 weeks. The beta is 0.57, so Cytosorbents's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -48.31% |
| 50-Day Moving Average | 0.96 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 49.39 |
| Average Volume (20 Days) | 141,514 |
Short Selling Information
The latest short interest is 1.37 million, so 2.50% of the outstanding shares have been sold short.
| Short Interest | 1.37M |
| Short Previous Month | 1.30M |
| Short % of Shares Out | 2.50% |
| Short % of Float | 2.98% |
| Short Ratio (days to cover) | 9.57 |
Income Statement
In the last 12 months, Cytosorbents had revenue of $37.74 million and -$18.67 million in losses. Loss per share was -$0.36.
| Revenue | 37.74M |
| Gross Profit | 23.67M |
| Operating Income | -21.31M |
| Pretax Income | -28.35M |
| Net Income | -18.67M |
| EBITDA | -19.73M |
| EBIT | -21.31M |
| Loss Per Share | -$0.36 |
Full Income StatementBalance Sheet
The company has $5.69 million in cash and $26.81 million in debt, giving a net cash position of -$21.12 million or -$0.39 per share.
| Cash & Cash Equivalents | 5.69M |
| Total Debt | 26.81M |
| Net Cash | -21.12M |
| Net Cash Per Share | -$0.39 |
| Equity (Book Value) | 13.00M |
| Book Value Per Share | 0.24 |
| Working Capital | 8.17M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.49 million and capital expenditures -$310,655, giving a free cash flow of -$18.80 million.
| Operating Cash Flow | -18.49M |
| Capital Expenditures | -310,655 |
| Free Cash Flow | -18.80M |
| FCF Per Share | -$0.34 |
Full Cash Flow StatementMargins
Gross margin is 62.71%, with operating and profit margins of -56.46% and -49.47%.
| Gross Margin | 62.71% |
| Operating Margin | -56.46% |
| Pretax Margin | -51.63% |
| Profit Margin | -49.47% |
| EBITDA Margin | -52.29% |
| EBIT Margin | -56.46% |
| FCF Margin | n/a |
Dividends & Yields
Cytosorbents does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.27% |
| Shareholder Yield | -19.27% |
| Earnings Yield | -37.32% |
| FCF Yield | -37.58% |
Analyst Forecast
The average price target for Cytosorbents is $4.67, which is 410.38% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.67 |
| Price Target Difference | 410.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 34.12% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 5, 2014. It was a reverse split with a ratio of 0.04:1.
| Last Split Date | Dec 5, 2014 |
| Split Type | Reverse |
| Split Ratio | 0.04:1 |
Scores
Cytosorbents has an Altman Z-Score of -8.15 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.15 |
| Piotroski F-Score | 4 |